Alloy Therapeutics

Founded 2020 · CIK 0001851943 · Biotech · Private

ATX-Gx mouse model and antibody discovery platform

alloytx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$147M
3 Form D · Apr 2026
6 months since last filing
Contracts
—
No federal contracts on record
Patents
19
0 granted · 19 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$74,999,875
Private capital raisedForm D · SEC$41,744,503
Private capital raisedForm D · SEC$30,020,259
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2220Immuneering Corp—$77M
2221Pheast Therapeutics—$50M
2222Tmunity Therapeutics—$140M
2223Alloy Therapeutics—$147M
2224ArriVent Biopharma—$191M
2225MOBIUS SCIENTIFIC INC.——
2226PMV Pharmaceuticals—$74M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • Errik AndersonDirector · Executive Officer
  • Piotr BobrowiczDirector · Executive Officer
  • Jason CammDirector
  • Jason ColomaDirector
  • Alaa HalawaDirector
  • Fabian HansenDirector
  • Christian KanadyDirector
  • Alex KolicichDirector
  • Ulrik NielsenDirector
  • Jay RosanelliExecutive Officer
  • Logan SnyderDirector · Executive Officer
  • Anthony SunDirector

Patents

USPTO · 0 granted of 19
  • Methods For Identifying Cognate Immunoglobulin Pairs From Individual B Cellsapplication
  • ANTI-CD3 Antibodies And Uses Thereofapplication
  • ANTI-WT1/HLA-A2 Antibody And Uses Thereofapplication
  • ANTI-CD3 Antibodies And Uses Thereofapplication
  • Methods For Identifying Cognate Immunoglobulin Pairs From Individual B Cellsapplication
  • ANTI-CD3 Antibodies And Uses Thereofapplication
  • ANTI-CD3 Antibodies And Uses Thereofapplication
  • ANTI-WT1/HLA-A2 Antibody And Uses Thereofapplication
  • ANTI-WT1/HLA-A2 Antibody And Uses Thereofapplication
  • ANTI-WT1/HLA-A2 Antibody And Uses Thereofapplication
  • ANTI-CD22 Antibodies And Uses Thereofapplication
  • ANTI-CD22 Antibodies And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.